Vertex Pharmaceuticals income statement

In fiscal 2025, Vertex Pharmaceuticals reported revenue of $12.00bn, up 8.9% on the year before, operating income of $4.17bn (a 34.8% margin) and net income of $3.95bn, or $15.32 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Vertex Pharmaceuticals: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0.1	0.1	1.4	1.5	1.2	0.6	1.0	1.7	2.5	3.0	4.2	6.2	7.6	8.9	9.9	11.0	12.0	12.6
Cost of revenue	—	—	—	—	—	—	—	0.2	0.3	0.4	0.5	0.7	0.9	1.1	1.3	1.5	1.7	1.8
Gross profit	—	—	—	—	—	—	—	1.5	2.2	2.6	3.6	5.5	6.7	7.9	8.6	9.5	10.4	10.8
Research and development	0.6	0.6	0.7	0.8	0.9	0.9	1.0	1.0	1.3	1.4	1.8	1.8	3.1	2.5	3.2	3.6	3.9	3.9
Selling, general and administrative	0.1	0.2	0.4	0.4	0.4	0.3	0.4	0.4	0.5	0.6	0.7	0.8	0.8	0.9	1.1	1.5	1.8	2.0
Operating income	−0.6	−0.7	0.1	0.0	−0.6	−0.7	−0.5	0.0	0.1	0.6	1.2	2.9	2.8	4.3	3.8	−0.2	4.2	4.8
Interest expense	0.0	0.0	0.0	0.0	—	—	—	—	0.1	0.1	0.1	0.1	—	0.1	0.0	0.0	0.0	—
Net interest income	—	—	—	—	—	—	—	—	—	—	−0.1	−0.1	−0.1	−0.1	−0.0	—	—	—
Income before tax	−0.6	−0.8	0.1	0.0	−0.6	−0.7	−0.6	−0.1	−0.0	0.6	1.4	3.1	2.7	4.2	4.4	0.2	4.6	5.3
Income tax	—	0.0	0.0	−0.0	−0.1	0.0	0.0	0.0	−0.1	−1.5	0.2	0.4	0.4	0.9	0.8	0.8	0.7	0.9
Net income	−0.6	−0.8	0.0	−0.1	−0.4	−0.7	−0.6	−0.1	0.3	2.1	1.2	2.7	2.3	3.3	3.6	−0.5	4.0	4.4
Diluted EPS	−$3.71	−$3.77	$0.14	−$0.50	−$1.98	−$3.14	−$2.31	−$0.46	$1.04	$8.09	$4.51	$10.29	$9.01	$12.82	$13.89	−$2.08	$15.32	$17.19
Diluted shares (average)	173m	200m	209m	215m	225m	235m	241m	245m	253m	259m	261m	263m	260m	259m	261m	258m	258m	256m
EBITDA	−0.6	−0.7	0.1	0.1	−0.6	−0.6	−0.4	0.1	0.2	0.7	1.3	3.0	2.9	4.5	4.0	−0.0	4.4	5.0

US$ millions unless shown otherwise. Fiscal quarters.

Vertex Pharmaceuticals: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	2,772	2,912	2,770	2,965	3,076	3,190	2,987	3,334
Cost of revenue	393	423	363	408	415	466	393	489
Gross profit	2,379	2,489	2,407	2,557	2,662	2,724	2,594	2,845
Research and development	876	999	980	978	978	974	962	994
Selling, general and administrative	372	378	396	425	445	487	494	582
Operating income	1,116	1,026	630	1,151	1,186	1,206	1,138	1,247
Interest expense	8	3	3	4	3	3	—	—
Income before tax	1,224	1,137	730	1,283	1,299	1,331	1,253	1,392
Income tax	179	224	84	250	216	140	222	292
Net income	1,045	913	646	1,033	1,083	1,191	1,031	1,100
Diluted EPS	$4.01	$3.53	$2.49	$3.99	$4.20	$4.64	$4.02	$4.31
EBITDA	1,170	1,073	679	1,203	1,240	1,262	1,194	1,303

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BIIB vs VRTX REGN vs VRTX INCY vs VRTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vertex Pharmaceuticals.